Landing Page - Blank - Sep 21, 11:02:07 – Save Our Sons Duchenne Foundation

LATEST STORIESFilter stories by category

PTC Therapeutics Provides Regulatory (FDA) Update on Translarna™

Muscular Dystrophy Australia - Inclusive Classrooms

Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT3247 in Duchenne Muscular Dystrophy

Genetic Webinar Series

Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.

Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

Wave Life Sciences Shares 48-Week Data from FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy

Duchenne Care Conference 2025

Sarepta Therapeutics Shares Safety Update on ELEVIDYS

Dyne Therapeutics Announces New Long-Term Clinical Data

Edgewise Therapeutics Topline results from phase 2 Becker Canyon trial of Sevasemten

Update to the Duchenne Community from Percheron Therapeutics on Progress with Avicursen

No Life Insurance Discrimination For Those With a Genetic Condition

Final Letter for Philips Recall

Update to Urgent Product Defect Alert TGA Ref RC-2024-RN-00257-1- Philips Ref 2023-CC-SRC-039

Pfizer Phase 2 Daylight Study Update

Pfizer gene therapy clinical trials commence in Australia

“New Frontiers” Launched

GP Submission

SOSDF to capitalise on the Queensland Parliamentary Inquiry into Social Isolation and Loneliness

Are you on the Australian Neuromuscular Disease Registry (ANMDR)?

Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051

Commonwealth Inquiry into Independent Assessment For NDIS

Have Your Say On NDIS

SOSDF NDIS Information Session

SOSDF Carriers Information Session

NSW Parliamentary Inquiry – Rural, Regional and Remote Health and Hospital Services.

Funding towards the position of Neuromuscular Clinical Trials Staff Specialist Neurologist, held by Dr. Ian Woodcock.

Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy

Commonwealth Parliamentary Inquiry New Drugs and Novel Medical Technologies

Alex Scollard Memorial PHD Scholarship

Save Our Sons Duchenne Foundation Nurses Program – The Royal Children’s Hospital in Melbourne

Duchenne & Becker muscular dystrophy, a guide for NDIS Planning

NDIS Virtual Town Hall

SOSDF Nurses Program Perth Children’s Hospital - Exclusive Neuromuscular Nurse

We need your stories - Parliamentary Inquiry into new drugs and novel medical technologies

Save Our Sons Duchenne Foundation Submission to the Federal Department of Education, Skills and Employment. 2020 Review of the Disability Standards for Education 2020

SOSDF Enhancing Quality-of-Life (EQOL) Program